Pharmaceutical Product Development LLC (PPD) recently announced that it has accepted two different U.S. government contracts from the U.S. Army and from BARDA to further research and develop pharmaceutical products.
The goal is to improve the health outcomes for members of the armed forces service as well as to assist in testing the efficiency of the avian influenza vaccine stockpile in the U.S.
The U.S. Army chose PPD to offer medical product development and research services to improve the readiness of preventative care and high quality medical care. In addition, PPD will optimize the survival of armed forces personnel who are serving on battlefields around the world.
The second agreement is between PPD and the Biomedical Advanced Research and Development Authority (BARDA) Medical Countermeasures Clinical Study Network. This agreement requires PPD to use its robust vaccine capabilities to further research in the U.S. Department of Health and Human Services.
“PPD is pleased to contribute to the important missions of improving health outcomes for armed services personnel and helping protect the people of the U.S. against the threat of pandemic influenza,” Bill Sharbaugh, chief operating officer of PPD, said. “Our integrated services, including deep clinical and laboratory expertise, enable us to provide the medical and technical knowledge necessary to help ensure these vital programs succeed.”
